KeyCorp Predicts Exagen's FY2026 Earnings (NASDAQ:XGN)

Key Points

• KeyCorp has issued a FY2026 earnings forecast for Exagen, projecting an earnings per share of ($0.31), while the current consensus estimate is ($0.88) per share.
• Exagen recently reported quarterly earnings of ($0.18) EPS, meeting analysts' expectations, and generated $17.20 million in revenue for the quarter.
• A majority of analysts have a buy rating on Exagen, with the stock's average price target set at $10.50.

Exagen Inc. (NASDAQ:XGN - Free Report) - Stock analysts at KeyCorp issued their FY2026 EPS estimates for Exagen in a research report issued to clients and investors on Tuesday, July 29th. KeyCorp analyst P. Knight expects that the company will post earnings of ($0.31) per share for the year. KeyCorp has a "Overweight" rating and a $12.00 price target on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share.

A number of other brokerages also recently issued reports on XGN. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $10.00 price target on shares of Exagen in a research report on Wednesday, July 30th. Craig Hallum started coverage on Exagen in a research report on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 target price on the stock. Canaccord Genuity Group boosted their price target on Exagen from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Wednesday, July 30th. UBS Group reiterated an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Exagen in a report on Wednesday, May 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $11.25.

Exagen Stock Up 2.3%

Shares of XGN stock traded up $0.20 during trading hours on Thursday, reaching $8.83. 128,545 shares of the company's stock were exchanged, compared to its average volume of 231,305. The stock's 50 day moving average is $7.19 and its 200-day moving average is $5.46. The company has a market cap of $194.15 million, a price-to-earnings ratio of -9.92 and a beta of 1.61. The company has a current ratio of 4.95, a quick ratio of 4.95 and a debt-to-equity ratio of 1.06. Exagen has a fifty-two week low of $1.78 and a fifty-two week high of $9.10.

Exagen (NASDAQ:XGN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, hitting analysts' consensus estimates of ($0.18). The company had revenue of $17.20 million during the quarter, compared to the consensus estimate of $16.25 million. Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%.

Institutional Investors Weigh In On Exagen

Hedge funds have recently modified their holdings of the company. Northern Trust Corp boosted its stake in shares of Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after acquiring an additional 2,630 shares in the last quarter. Virtu Financial LLC purchased a new position in Exagen in the 4th quarter valued at about $46,000. Toronto Dominion Bank purchased a new position in Exagen in the 4th quarter valued at about $3,655,000. Corient Private Wealth LLC purchased a new position in Exagen in the 4th quarter valued at about $45,000. Finally, Marshall Wace LLP purchased a new position in Exagen in the 4th quarter valued at about $66,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).